Autres langues AIM Vaccine Co., Ltd.

Actions

6660

CNE100005KF2

Temps Différé Hong Kong S.E. Autres places de cotation 10:09:05 07/06/2024			Varia. 5j.	Varia. 1 janv.
6,89 ^HKD	-2,68 %		+4,39 %	-12,23 %

05/06	AIM Vaccine soumet des pré-demandes d'essais cliniques pour des vaccins ARNm contre le virus respiratoire syncytial (VRS) et le zona	MT
04/06	Aim Vaccine Co. annonce la soumission de demandes préalables d'essais cliniques pour deux vaccins à ARNm contre le virus respiratoire syncytial (VRS) et le zona d'Aim Vaccine	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AIM Vaccine Submits Pre-Applications for Clinical Trials for MRNA RSV, Shingles Vaccines	05/06
Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus And Shingles/Herpes Zoster of Aim Vaccine	04/06
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	28/03
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	28/03
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine	28/03
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)	28/03
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine	27/03
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine	26/03
AIM Vaccine Files Pre-Application for Marketing Registration of its Pneumonia Vaccine	05/03
AIM Vaccine Boosts Development of Iterative Pneumonia Series Vaccines	04/03
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4%	04/03
AIM Vaccine Advances Trial of Meningococcal Vaccine in China; Shares Fall 4%	04/03
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%	04/03
AIM Vaccine Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine; Shares Fall 3%	04/03
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine	04/03
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	04/03
Aim Vaccine Co., Ltd. Announces Completion of the Layout of Iterative Rabies Vaccine Products and Fully Advancing the Research and Development of the Product Series	04/03
AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine	04/03
Aim Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues AIM Vaccine Co., Ltd.

Actions

6660

CNE100005KF2

Autres langues

Filtres